Andrea D. Burmeister

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

J. Schlom, R. Madan, J. Marté, 2019, Clinical Cancer Research.

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

S. Salas, J. Schlom, B. Cho, 2020, Journal for ImmunoTherapy of Cancer.

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

S. Steinberg, J. Schlom, R. Madan, 2019, The oncologist.

Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers.

J. Schlom, R. Madan, J. Marté, 2018 .

Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies

A. Rolfe, S. Salas, J. Schlom, 2019, Clinical Trials.